[
  {
    "ts": null,
    "headline": "PGIM Jennison Blend Fund Q4 2024 Commentary",
    "summary": "PGIM Jennison Blend Fund Q4 2024 Commentary",
    "url": "https://finnhub.io/api/news?id=e8c81c0527072f874f76c8eb4c6106afdf4f82c6ccb52e4adcc553cb3fbe9e17",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743206100,
      "headline": "PGIM Jennison Blend Fund Q4 2024 Commentary",
      "id": 133526379,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e8c81c0527072f874f76c8eb4c6106afdf4f82c6ccb52e4adcc553cb3fbe9e17"
    }
  },
  {
    "ts": null,
    "headline": "Invest in UnitedHealth Group, not Eli Lilly: Good Buy or Goodbye",
    "summary": "In the latest Good Buy or Goodbye, Regan Capital chief investment officer Skyler Weinand joins Market Domination host Julie Hyman to break down which stock is a good buy and what stock should be avoided. Weinand recommends investing in UnitedHealth Group (UNH), as the company is trading at an attractive P/E ratio. He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=163e60a8c12179f66f5736696dcbbc43119a4308e213c76a6f558349413c57c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743195357,
      "headline": "Invest in UnitedHealth Group, not Eli Lilly: Good Buy or Goodbye",
      "id": 133527536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the latest Good Buy or Goodbye, Regan Capital chief investment officer Skyler Weinand joins Market Domination host Julie Hyman to break down which stock is a good buy and what stock should be avoided. Weinand recommends investing in UnitedHealth Group (UNH), as the company is trading at an attractive P/E ratio. He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=163e60a8c12179f66f5736696dcbbc43119a4308e213c76a6f558349413c57c6"
    }
  },
  {
    "ts": null,
    "headline": "NEW YORK MARKET CLOSE: Shares lower on tariff strife, higher inflation",
    "summary": "NEW YORK MARKET CLOSE: Shares lower on tariff strife, higher inflation",
    "url": "https://finnhub.io/api/news?id=f5ccd156fe0b2afcfb033297dc05d233900e4cf52d26a1e9d4c945b7c97c596f",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743193824,
      "headline": "NEW YORK MARKET CLOSE: Shares lower on tariff strife, higher inflation",
      "id": 133524802,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f5ccd156fe0b2afcfb033297dc05d233900e4cf52d26a1e9d4c945b7c97c596f"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=ae3ddf31a880de1116406de17300190b2e0ca0b2f561542a89cdb452859a9f37",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743181860,
      "headline": "Health Care Roundup: Market Talk",
      "id": 133544012,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=ae3ddf31a880de1116406de17300190b2e0ca0b2f561542a89cdb452859a9f37"
    }
  },
  {
    "ts": null,
    "headline": "European Equities Track Lower in Friday Trading; Apple, Meta May Face Lower EU Digital Markets Act Fines",
    "summary": "The European stock markets were tracking lower in Friday trading as The Stoxx Europe 600 fell 0.69%,",
    "url": "https://finnhub.io/api/news?id=fe2ee1afdfe79b214892a683c768fe95cf950ae3f4162933498e01b4bb179cd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743178728,
      "headline": "European Equities Track Lower in Friday Trading; Apple, Meta May Face Lower EU Digital Markets Act Fines",
      "id": 133523766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The European stock markets were tracking lower in Friday trading as The Stoxx Europe 600 fell 0.69%,",
      "url": "https://finnhub.io/api/news?id=fe2ee1afdfe79b214892a683c768fe95cf950ae3f4162933498e01b4bb179cd6"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1",
    "summary": "Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1",
    "url": "https://finnhub.io/api/news?id=dc03fc60b4ecb2ea593ade0a77b070f2d4c0e94ab19d88266ae407326477b63c",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743178675,
      "headline": "Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1",
      "id": 133544015,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1",
      "url": "https://finnhub.io/api/news?id=dc03fc60b4ecb2ea593ade0a77b070f2d4c0e94ab19d88266ae407326477b63c"
    }
  },
  {
    "ts": null,
    "headline": "European committee says Lilly Alzheimer's drug shouldn't get marketing approval",
    "summary": "A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling.  The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.  The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion.",
    "url": "https://finnhub.io/api/news?id=258a1bfec0db204a6228c56c3c5c64a080641100fc67c8bc754b718595afd8a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743172274,
      "headline": "European committee says Lilly Alzheimer's drug shouldn't get marketing approval",
      "id": 133523767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling.  The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.  The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion.",
      "url": "https://finnhub.io/api/news?id=258a1bfec0db204a6228c56c3c5c64a080641100fc67c8bc754b718595afd8a9"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Ken Fisher’s #2 Low Vol Stock Pick: Eli Lilly & Company (LLY)",
    "summary": "We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher In this article, we are going to take a look at where Eli Lilly & Company (NYSE:LLY) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned […]",
    "url": "https://finnhub.io/api/news?id=bffcb3a9208b49f56d711e755d7c2e9020fc252c1f4a263a7dd9235c07bc5e26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743168789,
      "headline": "Billionaire Ken Fisher’s #2 Low Vol Stock Pick: Eli Lilly & Company (LLY)",
      "id": 133508544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher In this article, we are going to take a look at where Eli Lilly & Company (NYSE:LLY) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned […]",
      "url": "https://finnhub.io/api/news?id=bffcb3a9208b49f56d711e755d7c2e9020fc252c1f4a263a7dd9235c07bc5e26"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=fe23d84e23a5082e4c994f734fe992dc7c1e67b284a60c5793cb23cae3fd5d44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743166815,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 133523770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=fe23d84e23a5082e4c994f734fe992dc7c1e67b284a60c5793cb23cae3fd5d44"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs, Tech Sluggishness, Gold, Bitcoin, And Inflation",
    "summary": "Contextualizing auto tariff news for investors, tech sluggishness, Novo Nordisk, GameStop slide. Gold, Bitcoin, volatility and inflation.",
    "url": "https://finnhub.io/api/news?id=fad5c8f856e5b4cbcc85ebd4ffaa35bdfc7c47df4e1cdd0f526ae24f25438c9a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743166800,
      "headline": "Tariffs, Tech Sluggishness, Gold, Bitcoin, And Inflation",
      "id": 133519400,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200759945/image_2200759945.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Contextualizing auto tariff news for investors, tech sluggishness, Novo Nordisk, GameStop slide. Gold, Bitcoin, volatility and inflation.",
      "url": "https://finnhub.io/api/news?id=fad5c8f856e5b4cbcc85ebd4ffaa35bdfc7c47df4e1cdd0f526ae24f25438c9a"
    }
  },
  {
    "ts": null,
    "headline": "BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag",
    "summary": "Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2025 guidance in its quarterly results.  BofA global research predicted in a note a 2% cut to the company's full-year sales guidance and expects a new sales growth range for the year of between 14% and 22%.  \"1Q seems a possible miss on sluggish Ozempic/Wegovy trends, worse currency (impact) and possibly higher (selling, general and administrative expenses) needed for demand creation and to convince physicians that supply is back,\" BofA said.",
    "url": "https://finnhub.io/api/news?id=248e4e5240cb3b49fb675e92ebc500b50c77dcd767fc8c0df7c1d1d1ca7b6f80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743165685,
      "headline": "BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag",
      "id": 133523771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2025 guidance in its quarterly results.  BofA global research predicted in a note a 2% cut to the company's full-year sales guidance and expects a new sales growth range for the year of between 14% and 22%.  \"1Q seems a possible miss on sluggish Ozempic/Wegovy trends, worse currency (impact) and possibly higher (selling, general and administrative expenses) needed for demand creation and to convince physicians that supply is back,\" BofA said.",
      "url": "https://finnhub.io/api/news?id=248e4e5240cb3b49fb675e92ebc500b50c77dcd767fc8c0df7c1d1d1ca7b6f80"
    }
  },
  {
    "ts": null,
    "headline": "CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update",
    "summary": "By Colin Kellaher A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. ...",
    "url": "https://finnhub.io/api/news?id=138c73225112c6cc856c5e81f4f4480422f9511a32f6773596ea8eda6e10c7ce",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743163285,
      "headline": "CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update",
      "id": 133515705,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. ...",
      "url": "https://finnhub.io/api/news?id=138c73225112c6cc856c5e81f4f4480422f9511a32f6773596ea8eda6e10c7ce"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly adds Alzheimer’s treatment options to LillyDirect telehealth platform",
    "summary": "The platform features Healthgrades, a tool intended to connect Alzheimer's patients to experienced local clinicians.",
    "url": "https://finnhub.io/api/news?id=50365dc599c107090b4cb44f3a8ca8104a1395b16515ed91a8cb4283f0461d36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743157859,
      "headline": "Eli Lilly adds Alzheimer’s treatment options to LillyDirect telehealth platform",
      "id": 133507748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The platform features Healthgrades, a tool intended to connect Alzheimer's patients to experienced local clinicians.",
      "url": "https://finnhub.io/api/news?id=50365dc599c107090b4cb44f3a8ca8104a1395b16515ed91a8cb4283f0461d36"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "summary": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743155082,
      "headline": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
      "id": 133508460,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2ec9b46a156413c058393a72e5bee50e867a91233b35571d7b5b27f08d74bd75"
    }
  },
  {
    "ts": null,
    "headline": "CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug",
    "summary": "By Colin Kellaher A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. ...",
    "url": "https://finnhub.io/api/news?id=3989eef80c3b6468b72547e003df361e735c727210993c9e1fd8ea6cae0b9a15",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743150809,
      "headline": "CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug",
      "id": 133507698,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. ...",
      "url": "https://finnhub.io/api/news?id=3989eef80c3b6468b72547e003df361e735c727210993c9e1fd8ea6cae0b9a15"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Remains Confident In The Safety And Effectiveness Of Donanemab",
    "summary": "Eli Lilly and Co: * ELI LILLY - REMAINS CONFIDENT IN THE SAFETY ANDEFFECTIVENESS OFDONANEMAB * ELI LILLY SAYS WILL SEEK RE-EXAMINATION BY CHMP - WEBSITEFurther company...",
    "url": "https://finnhub.io/api/news?id=e298a12de1a5f000fb0c538f89372ef44b280878ac3cfbcc57eb414ca740f9db",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743148264,
      "headline": "Eli Lilly Remains Confident In The Safety And Effectiveness Of Donanemab",
      "id": 133507357,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * ELI LILLY - REMAINS CONFIDENT IN THE SAFETY ANDEFFECTIVENESS OFDONANEMAB * ELI LILLY SAYS WILL SEEK RE-EXAMINATION BY CHMP - WEBSITEFurther company...",
      "url": "https://finnhub.io/api/news?id=e298a12de1a5f000fb0c538f89372ef44b280878ac3cfbcc57eb414ca740f9db"
    }
  },
  {
    "ts": null,
    "headline": "Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500",
    "summary": "Each one of their moves may not be right for your particular investment strategy, but you may find certain ones that offer just what you're looking for.  If  you're looking for a low-risk growth stock that also happens to be outperforming the S&P 500 (SNPINDEX: ^GSPC) so far this year, it's time to consider a recent move made by three billionaires.  Stanley Druckenmiller of the Duquesne Family Office, Chase Coleman of Tiger Global Management, and Stephen Mandel Jr. of Lone Pine Capital each bought shares of a stock that operates in an industry known for steady performance, regardless of the market environment.",
    "url": "https://finnhub.io/api/news?id=30410eb3d7df995019f0e218147d988eea31075e4a3bc37b932955235d038553",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743147900,
      "headline": "Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500",
      "id": 133507749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Each one of their moves may not be right for your particular investment strategy, but you may find certain ones that offer just what you're looking for.  If  you're looking for a low-risk growth stock that also happens to be outperforming the S&P 500 (SNPINDEX: ^GSPC) so far this year, it's time to consider a recent move made by three billionaires.  Stanley Druckenmiller of the Duquesne Family Office, Chase Coleman of Tiger Global Management, and Stephen Mandel Jr. of Lone Pine Capital each bought shares of a stock that operates in an industry known for steady performance, regardless of the market environment.",
      "url": "https://finnhub.io/api/news?id=30410eb3d7df995019f0e218147d988eea31075e4a3bc37b932955235d038553"
    }
  },
  {
    "ts": null,
    "headline": "Negative recommendation in the EU for Eli Lilly's Alzheimer's drug Kisunla",
    "summary": "The European Medicines Agency's expert panel rejected pharmaceutical giant Eli Lilly's Alzheimer's drug Kisunla, pointing out that the risk of severe brain swelling does not outweigh the treatment's...",
    "url": "https://finnhub.io/api/news?id=6189c784b25595276c4a47a0a3b29b60eba220a5a7ab3a262f2655ef1a7a111b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743146842,
      "headline": "Negative recommendation in the EU for Eli Lilly's Alzheimer's drug Kisunla",
      "id": 133507220,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The European Medicines Agency's expert panel rejected pharmaceutical giant Eli Lilly's Alzheimer's drug Kisunla, pointing out that the risk of severe brain swelling does not outweigh the treatment's...",
      "url": "https://finnhub.io/api/news?id=6189c784b25595276c4a47a0a3b29b60eba220a5a7ab3a262f2655ef1a7a111b"
    }
  },
  {
    "ts": null,
    "headline": "EU regulator rejects Eli Lilly's Alzheimer's drug",
    "summary": "The European Union's drugsregulator on Friday rejected Eli Lilly's Alzheimer'sdrug, saying the risk of serious brain swelling did not outweighthe treatment's small impact on slowing cognitive...",
    "url": "https://finnhub.io/api/news?id=771af3600e048796239c3834fae67d66cb72b345cdc6747d51af8949d2eaf66e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743145453,
      "headline": "EU regulator rejects Eli Lilly's Alzheimer's drug",
      "id": 133507055,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The European Union's drugsregulator on Friday rejected Eli Lilly's Alzheimer'sdrug, saying the risk of serious brain swelling did not outweighthe treatment's small impact on slowing cognitive...",
      "url": "https://finnhub.io/api/news?id=771af3600e048796239c3834fae67d66cb72b345cdc6747d51af8949d2eaf66e"
    }
  },
  {
    "ts": null,
    "headline": "EMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla",
    "summary": "EMA's CHMP: * EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETINGAUTHORISATIONFOR KISUNLA * EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETINGAUTHORISATION FOR PEMAZYRE...",
    "url": "https://finnhub.io/api/news?id=eee6b723d76863daff5002504d5a2366750f94ca8619bf2114274e676b7acd13",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743145197,
      "headline": "EMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla",
      "id": 133507046,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "EMA's CHMP: * EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETINGAUTHORISATIONFOR KISUNLA * EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETINGAUTHORISATION FOR PEMAZYRE...",
      "url": "https://finnhub.io/api/news?id=eee6b723d76863daff5002504d5a2366750f94ca8619bf2114274e676b7acd13"
    }
  },
  {
    "ts": null,
    "headline": "EU medicines regulator rejects Eli Lilly's Alzheimer's drug",
    "summary": "The European Union's drugsregulator on Friday rejected Eli Lilly's Alzheimer'sdrug Kisunla, saying the risk of serious brain swelling did notoutweigh the treatment's small impact on slowing...",
    "url": "https://finnhub.io/api/news?id=e119ab71ddad8d1b0a3c5657ca7591b24b847fd8690a8b6fe322fa69f400459a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743144790,
      "headline": "EU medicines regulator rejects Eli Lilly's Alzheimer's drug",
      "id": 133506991,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The European Union's drugsregulator on Friday rejected Eli Lilly's Alzheimer'sdrug Kisunla, saying the risk of serious brain swelling did notoutweigh the treatment's small impact on slowing...",
      "url": "https://finnhub.io/api/news?id=e119ab71ddad8d1b0a3c5657ca7591b24b847fd8690a8b6fe322fa69f400459a"
    }
  }
]